Kyowa Kirin International
NICE recommends first new X-linked hypophosphataemia therapy in over 30 years
October 10, 2018Research and Development, Sales and Marketing Crysvita, Kyowa Kirin International, NHS, NICE, X-linked hypophosphataemia, pharma
NICE has announced its evidence-based recommendation that Kyowa Kirin International’s Crysvita (burosumab) be made available on the NHS for the …
Latest content
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
AI: an early warning system for patient safety
November 3, 2026
